CTOs on the Move

XyloCor

www.xylocor.com

 
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alexander Gaidamaka
Senior Vice President of Technology, Manufacturing and Quality Profile

Funding

XyloCor raised $17M on 12/06/2018
XyloCor raised $22.6M on 03/22/2021

Similar Companies

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prothena

Prothena Corporation plc (Nasdaq: PRTA) Prothena is a global biotechnology company seeking to fundamentally alter the course of progressive diseases. We are a late-stage clinical company focused on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. Our team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prothena`s pipeline focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and our antibody-based product candidates target a number of potential indications, including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), ATTR amyloidosis (PRX004), and novel cell adhesion targets involved in psoriasis, psoriatic arthritis and other inflammatory diseases (PRX003). Prior to December 2012, Prothena’s business operated as part of Elan Corporation, plc. Prothena’s business consists of a substantial portion of Elan’s former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan’s stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012.

Axion Pharmaceuticals

Axion Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HiFiBiO - High Fidelity Biology

HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.

Trinity Biomedical

Trinity Biomedical is a Menomonee Falls, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.